Top News
Next Story
NewsPoint

Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia

Send Push
ET Health
16th May, 2019 11:13 IST
ZURICH: Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia.

"Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard-of-care," Roche's Chief Medical Officer Sandra Horning said in a statement.
Explore more on Newspoint
Loving Newspoint? Download the app now